LongBio Pharma (Suzhou) Co., Ltd. Class H

As of December 31, 2025, LongBio Pharma (Suzhou) Co., Ltd. Class H has 74.19M shares outstanding.

As of December 31, 2025, LongBio Pharma (Suzhou) Co., Ltd. Class H maintains a current ratio of 2.42, meaning it holds 2.4x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 26.99, indicating elevated leverage, while an interest coverage ratio of -8.98 demonstrates limited ability to service its debt obligations.

These figures cover the twelve months ended December 31, 2025. Return on assets (ROA) is negative at -93.28, reflecting losses generated across the asset base. The company generates approximately - - in revenue per employee across its workforce of 85.00, a quick read on workforce productivity versus industry peers.

These figures are as of the close on October 22, 2026.

Over the twelve months ended December 31, 2025, LongBio Pharma (Suzhou) Co., Ltd. Class H generated - - in revenue and converted that into -195.40M in net income, yielding earnings per share of -2.63. EBITDA reached -168.40M, while operating income came in at -176.86M.

As of December 31, 2025, LongBio Pharma (Suzhou) Co., Ltd. Class H holds 212.72M in cash and equivalents against 42.20M in total debt, resulting in a net debt position of -67.81M. Total book value stands at 156.38M, with working capital of 132.01M providing operational flexibility.

LongBio Pharma (Suzhou) Co., Ltd. Class H produced -134.70M in operating cash flow over the twelve months ended December 31, 2025. After subtracting -4.88M in capital expenditures, free cash flow totaled -139.58M - equivalent to -1.88 per share.